The US Food and Drug Administration (FDA) is alerting physicians and patients that individuals undergoing treatment with immune-suppressing ofatumumab or rituximab have an increased risk of reactivating hepatitis B virus (HBV). The alerts, in the form of boxed warnings, the strongest warnings issued by the FDA, were issued September 25.
Ofatumumab, approved in 2009, is used to treat chronic lymphocytic leukemia in patients with further disease after treatment with the anticancer drugs fludarabine and alemtuzumab. Rituximab, approved in 1997, is used to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia, as well as rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis. Both drugs are classified as anti–CD20-directed monoclonal antibodies.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.